Erratum to Differential induction of apoptosis, interferon signaling, and phagocytosis in macrophages infected with a panel of attenuated and nonattenuated poxviruses [J Virol, 88, 10, (2014) 5511-5523, DOI:10.1128/JVI.00468-14];Differential induction of apoptosis, interferon signaling, and phagocytosis in macrophages infected with a panel of attenuated and nonattenuated poxviruses

Journal of Virology

Volumn 88, Issue 10, 2014, Pages 5511-5523

  Royo, Sandra ^a   Sainz, Bruno ^b   Hernández Jiménez, Enrique ^c   Reyburn, Hugh ^d   López Collazo, Eduardo ^c   Guerra, Susana ^a  

^a UNIVERSIDAD AUTÓNOMA DE MADRID   (Spain)

^b Structural Biology and Biocomputing Programme   (Spain)

^c HOSPITAL UNIVERSITARIO LA PAZ   (Spain)

^d CENTRO NACIONAL DE BIOTECNOLOGÍA   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

BETA INTERFERON; MESSENGER RNA; POXVIRUS VECTOR;

APOPTOSIS; ARTICLE; BIOASSAY; CONTROLLED STUDY; GENE EXPRESSION; HUMAN; HUMAN CELL; IN VITRO STUDY; INNATE IMMUNITY; MACROPHAGE; MICROARRAY ANALYSIS; MODIFIED VACCINIA ANKARA VIRUS; NONHUMAN; PHAGOCYTOSIS; PHENOTYPE; POXVIRUS; POXVIRUS INFECTION; PRIORITY JOURNAL; PROTEIN SECRETION; VACCINIA VIRUS; VIRUS ATTENUATION; VIRUS CELL INTERACTION; VIRUS STRAIN;

APOPTOSIS; CELLS, CULTURED; GENE EXPRESSION PROFILING; HUMANS; INTERFERONS; MACROPHAGES; MICROARRAY ANALYSIS; PHAGOCYTOSIS; POXVIRIDAE; SIGNAL TRANSDUCTION;

EID: 84899071116     PISSN: 0022538X     EISSN: 10985514     Source Type: Journal    
DOI: 10.1128/JVI.00485-16     Document Type: Erratum

References (49)

1. Franchini G, Gurunathan S, Baglyos L, Plotkin S, Tartaglia J. 2004. Poxvirus-based vaccine candidates for HIV: two decades of experience with special emphasis on canarypox vectors. Expert Rev. Vaccines 3:S75-S88. http://dx.doi.org/10.1586/14760584.3.4.S75.
2. Crotty S, Felgner P, Davies H, Glidewell J, Villarreal L, Ahmed R. 2003. Cutting edge: long-term B cell memory in humans after smallpox vaccination. J. Immunol. 171:4969-4973.
3. Antoine G, Scheiflinger F, Dorner F, Falkner FG. 1998. The complete genomic sequence of the modified vaccinia Ankara strain: comparison with other orthopoxviruses. Virology 244:365-396. http://dx.doi.org/10 .1006/viro.1998.9123.
4. Gomez CE, Perdiguero B, Garcia-Arriaza J, Esteban M. 2013. Clinical applications of attenuated MVA poxvirus strain. Expert Rev. Vaccines 12:1395-1416. http://dx.doi.org/10.1586/14760584.2013.845531.
5. Meyer H, Sutter G, Mayr A. 1991. Mapping of deletions in the genome of the highly attenuated vaccinia virus MVA and their influence on virulence. J. Gen. Virol. 72:1031-1038. http://dx.doi.org/10.1099/0022-1317 -72-5-1031.
6. Moss B. 1996. Genetically engineered poxviruses for recombinant gene expression, vaccination, and safety. Proc. Natl. Acad. Sci. U. S. A. 93: 11341-11348. http://dx.doi.org/10.1073/pnas.93.21.11341.
7. Schneider J, Gilbert SC, Blanchard TJ, Hanke T, Robson KJ, Hannan CM, Becker M, Sinden R, Smith GL, Hill AV. 1998. Enhanced immunogenicity for CD8+ T cell induction and complete protective efficacy of malaria DNA vaccination by boosting with modified vaccinia virus Ankara. Nat. Med. 4:397-402. http://dx.doi.org/10.1038/nm0498-397.
8. Cebere I, Dorrell L, McShane H, Simmons A, McCormack S, Schmidt C, Smith C, Brooks M, Roberts JE, Darwin SC, Fast PE, Conlon C, Rowland-Jones S, McMichael AJ, Hanke T. 2006. Phase I clinical trial safety of DNA-and modified virus Ankara-vectored human immunodeficiency virus type 1 (HIV-1) vaccines administered alone and in a primeboost regime to healthy HIV-1-uninfected volunteers. Vaccine 24:417-425. http://dx.doi.org/10.1016/j.vaccine.2005.08.041.
9. Corona Gutierrez CM, Tinoco A, Navarro T, Contreras ML, Cortes RR, Calzado P, Reyes L, Posternak R, Morosoli G, Verde ML, Rosales R. 2004. Therapeutic vaccination with MVA E2 can eliminate precancerous lesions (CIN 1, CIN 2, and CIN 3) associated with infection by oncogenic human papillomavirus. Hum. Gene Ther. 15:421-431. http://dx.doi.org /10.1089/10430340460745757.
10. Gilbert SC, Moorthy VS, Andrews L, Pathan AA, McConkey SJ, Vuola JM, Keating SM, Berthoud T, Webster D, McShane H, Hill AV. 2006. Synergistic DNA-MVA prime-boost vaccination regimes for malaria and tuberculosis. Vaccine 24:4554-4561. http://dx.doi.org/10.1016/j.vaccine .2005.08.048.
11. Harrop R, Connolly N, Redchenko I, Valle J, Saunders M, Ryan MG, Myers KA, Drury N, Kingsman SM, Hawkins RE, Carroll MW. 2006. Vaccination of colorectal cancer patients with modified vaccinia Ankara delivering the tumor antigen 5T4 (TroVax) induces immune responses which correlate with disease control: a phase I/II trial. Clin. Cancer Res. 12:3416-3424. http://dx.doi.org/10.1158/1078-0432.CCR-05-2732.
12. Belyakov IM, Earl P, Dzutsev A, Kuznetsov VA, Lemon M, Wyatt LS, Snyder JT, Ahlers JD, Franchini G, Moss B, Berzofsky JA. 2003. Shared modes of protection against poxvirus infection by attenuated and conventional smallpox vaccine viruses. Proc. Natl. Acad. Sci. U. S. A. 100:9458-9463. http://dx.doi.org/10.1073/pnas.1233578100.
13. Tartaglia J, Perkus ME, Taylor J, Norton EK, Audonnet JC, Cox WI, Davis SW, van der Hoeven J, Meignier B, Riviere M, Languet B, Paoletti E. 1992. NYVAC: a highly attenuated strain of vaccinia virus. Virology 188:217-232. http://dx.doi.org/10.1016/0042-6822(92)90752-B.
14. Kanesa-thasan N, Smucny JJ, Hoke CH, Marks DH, Konishi E, Kurane I, Tang DB, Vaughn DW, Mason PW, Shope RE. 2000. Safety and immunogenicity of NYVAC-JEV and ALVAC-JEV attenuated recombinant Japanese encephalitis virus-poxvirus vaccines in vaccinianonimmune and vaccinia-immune humans. Vaccine 19:483-491. http: //dx.doi.org/10.1016/S0264-410X(00)00191-2.
15. Myagkikh M, Alipanah S, Markham PD, Tartaglia J, Paoletti E, Gallo RC, Franchini G, Robert-Guroff M. 1996. Multiple immunizations with attenuated poxvirus HIV type 2 recombinants and subunit boosts required for protection of rhesus macaques. AIDS Res. Hum. Retroviruses 12:985-992. http://dx.doi.org/10.1089/aid.1996.12.985.
16. Sivanandham M, Shaw P, Bernik SF, Paoletti E, Wallack MK. 1998. Colon cancer cell vaccine prepared with replication-deficient vaccinia viruses encoding B7.1 and interleukin-2 induce antitumor response in syngeneic mice. Cancer Immunol. Immunother. 46:261-267. http://dx.doi .org/10.1007/s002620050486.
17. Ockenhouse CF, Sun PF, Lanar DE, Wellde BT, Hall BT, Kester K, Stoute JA, Magill A, Krzych U, Farley L, Wirtz RA, Sadoff JC, Kaslow DC, Kumar S, Church LW, Crutcher JM, Wizel B, Hoffman S, Lalvani A, Hill AV, Tine JA, Guito KP, de Taisne C, Anders R, Horii T, Paoletti E, Ballou WR. 1998. Phase I/IIa safety, immunogenicity, and efficacy trial of NYVAC-Pf7, a pox-vectored, multiantigen, multistage vaccine candidate for Plasmodium falciparum malaria. J. Infect. Dis. 177:1664-1673. http://dx.doi.org/10.1086/515331.
18. Parker RF, Bronson LH, Green RH. 1941. Further studies of the infectious unit of vaccinia. J. Exp. Med. 74:263-281. http://dx.doi.org/10.1084 /jem.74.3.263.
19. Buller RM, Palumbo GJ. 1991. Poxvirus pathogenesis. Microbiol. Rev. 55:80-122.
20. Martinez O, Leung LW, Basler CF. 2012. The role of antigen-presenting cells in filoviral hemorrhagic fever: gaps in current knowledge. Antiviral Res. 93:416-428. http://dx.doi.org/10.1016/j.antiviral.2012.01.011.
21. Rodgers B, Mims CA. 1981. Interaction of influenza virus with mouse macrophages. Infect. Immun. 31:751-757.
22. Rodriguez D, Rodriguez JR, Rodriguez JF, Trauber D, Esteban M. 1989. Highly attenuated vaccinia virus mutants for the generation of safe recombinant viruses. Proc. Natl. Acad. Sci. U. S. A. 86:1287-1291. http://dx.doi .org/10.1073/pnas.86.4.1287.
23. Rodriguez D, Esteban M, Rodriguez JR. 1995. Vaccinia virus A17L gene product is essential for an early step in virion morphogenesis. J. Virol. 69:4640-4648.
24. Guerra S, Lopez-Fernandez LA, Conde R, Pascual-Montano A, Harshman K, Esteban M. 2004. Microarray analysis reveals characteristic changes of host cell gene expression in response to attenuated modified vaccinia virus Ankara infection of human HeLa cells. J. Virol. 78:5820-5834. http://dx.doi.org/10.1128/JVI.78.11.5820-5834.2004.
25. Guerra S, Lopez-Fernandez LA, Garcia MA, Zaballos A, Esteban M. 2006. Human gene profiling in response to the active protein kinase, interferoninduced serine/threonine protein kinase (PKR), in infected cells. Involvement of the transcription factor ATF-3 IN PKR-induced apoptosis. J. Biol. Chem. 281:18734-18745. http://dx.doi.org/10.1074/jbc.M511983200.
26. Guerra S, Lopez-Fernandez LA, Pascual-Montano A, Munoz M, Harshman K, Esteban M. 2003. Cellular gene expression survey of vaccinia virus infection of human HeLa cells. J. Virol. 77:6493-6506. http://dx.doi.org /10.1128/JVI.77.11.6493-6506.2003.
27. Guerra S, Lopez-Fernandez LA, Pascual-Montano A, Najera JL, Zaballos A, Esteban M. 2006. Host response to the attenuated poxvirus vector NYVAC: upregulation of apoptotic genes and NF- B-responsive genes in infected HeLa cells. J. Virol. 80:985-998. http://dx.doi.org/10.1128/JVI.80 .2.985-998.2006.
28. Marti-Lliteras P, Regueiro V, Morey P, Hood DW, Saus C, Sauleda J, Agusti AG, Bengoechea JA, Garmendia J. 2009. Nontypeable Haemophilus influenzae clearance by alveolar macrophages is impaired by exposure to cigarette smoke. Infect. Immun. 77:4232-4242. http://dx.doi.org/10 .1128/IAI.00305-09.
29. Sharma S, tenOever BR, Grandvaux N, Zhou GP, Lin R, Hiscott J. 2003. Triggering the interferon antiviral response through an IKK-related pathway. Science 300:1148-1151. http://dx.doi.org/10.1126/science.1081315.
30. Guerra S, Najera JL, Gonzalez JM, Lopez-Fernandez LA, Climent N, Gatell JM, Gallart T, Esteban M. 2007. Distinct gene expression profiling after infection of immature human monocyte-derived dendritic cells by the attenuated poxvirus vectors MVA and NYVAC. J. Virol. 81:8707-8721. http://dx.doi.org/10.1128/JVI.00444-07.
31. Joffre OP, Segura E, Savina A, Amigorena S. 2012. Cross-presentation by dendritic cells. Nat. Rev. Immunol. 12:557-569. http://dx.doi.org/10.1038 /nri3254.
32. Ichikawa T, Nakao K, Nakata K, Hamasaki K, Takeda Y, Kajiya Y, Higashi S, Ohkubo K, Kato Y, Ishii N, Eguchi K. 2001. Geranylgeranylacetone induces antiviral gene expression in human hepatoma cells. Biochem. Biophys. Res. Commun. 280:933-939. http://dx.doi.org/10 .1006/bbrc.2000.4228.
33. Aderem A, Underhill DM. 1999. Mechanisms of phagocytosis in macrophages. Annu. Rev. Immunol. 17:593-623. http://dx.doi.org/10.1146 /annurev.immunol.17.1.593.
34. Smyth GK, Altman NS. 2013. Separate-channel analysis of two-channel microarrays: recovering inter-spot information. BMC Bioinformatics 14: 165. http://dx.doi.org/10.1186/1471-2105-14-165.
35. Yanguez E, Garcia-Culebras A, Frau A, Llompart C, Knobeloch KP, Gutierrez-Erlandsson S, Garcia-Sastre A, Esteban M, Nieto A, Guerra S. 2013. ISG15 regulates peritoneal macrophages functionality against viral infection. PLoS Pathog. 9:e1003632. http://dx.doi.org/10.1371/journal .ppat.1003632.
36. Klotman ME, Chang TL. 2006. Defensins in innate antiviral immunity. Nat. Rev. Immunol. 6:447-456. http://dx.doi.org/10.1038/nri1860.
37. Deng L, Dai P, Ding W, Granstein RD, Shuman S. 2006. Vaccinia virus infection attenuates innate immune responses and antigen presentation by epidermal dendritic cells. J. Virol. 80:9977-9987. http://dx.doi.org/10 .1128/JVI.00354-06.
38. Grandvaux N, tenOever BR, Servant MJ, Hiscott J. 2002. The interferon antiviral response: from viral invasion to evasion. Curr. Opin. Infect. Dis. 15:259-267. http://dx.doi.org/10.1097/00001432-200206000-00008.
39. Hotchin J, Seegal R. 1977. Virus-induced behavioral alteration of mice. Science 196:671-674. http://dx.doi.org/10.1126/science.854742.
40. Yoneyama M, Kikuchi M, Natsukawa T, Shinobu N, Imaizumi T, Miyagishi M, Taira K, Akira S, Fujita T. 2004. The RNA helicase RIG-I has an essential function in double-stranded RNA-induced innate antiviral responses. Nat. Immunol. 5:730 -737. http://dx.doi.org /10.1038/ni1087.
41. Servant MJ, tenOever B, LePage C, Conti L, Gessani S, Julkunen I, Lin R, Hiscott J. 2001. Identification of distinct signaling pathways leading to the phosphorylation of interferon regulatory factor 3. J. Biol. Chem. 276: 355-363. http://dx.doi.org/10.1074/jbc.M007790200.
42. Vogel SN, Friedman RM, Hogan MM. 2001. Measurement of antiviral activity induced by interferons alpha, beta, and gamma. Curr. Protoc. Immunol. Chapter 6:Unit 6.9. http://dx.doi.org/10.1002/0471142735 .im0609s37.
43. Perales-Linares R, Navas-Martin S. 2013. Toll-like receptor 3 in viral pathogenesis: friend or foe?. Immunology 140:153-167. http://dx.doi.org /10.1111/imm.12143.
44. Alcami A. 2003. Viral mimicry of cytokines, chemokines and their receptors. Nat. Rev. Immunol. 3:36-50. http://dx.doi.org/10.1038/nri980.
45. Beattie E, Paoletti E, Tartaglia J. 1995. Distinct patterns of IFN sensitivity observed in cells infected with vaccinia K3L-and E3L-mutant viruses. Virology 210:254-263. http://dx.doi.org/10.1006/viro.1995.1342.
46. Kotwal GJ, Isaacs SN, McKenzie R, Frank MM, Moss B. 1990. Inhibition of the complement cascade by the major secretory protein of vaccinia virus. Science 250:827-830. http://dx.doi.org/10.1126/science.2237434.
47. Symons JA, Alcami A, Smith GL. 1995. Vaccinia virus encodes a soluble type I interferon receptor of novel structure and broad species specificity. Cell 81:551-560. http://dx.doi.org/10.1016/0092-8674(95)90076-4.
48. Stack J, Haga IR, Schroder M, Bartlett NW, Maloney G, Reading PC, Fitzgerald KA, Smith GL, Bowie AG. 2005. Vaccinia virus protein A46R targets multiple Toll-like-interleukin-1 receptor adaptors and contributes to virulence. J. Exp. Med. 201:1007-1018. http://dx.doi.org/10.1084/jem .20041442.
49. Perdiguero B, Gomez CE, Najera JL, Sorzano CO, Delaloye J, Gonzalez-Sanz R, Jimenez V, Roger T, Calandra T, Pantaleo G, Esteban M. 2012. Deletion of the viral anti-apoptotic gene F1L in the HIV/AIDS vaccine candidate MVA-C enhances immune responses against HIV-1 antigens. PLoS One 7:e48524. http://dx.doi.org/10.1371/journal.pone.0048524.